Technical Name Methodkit for diagnosing Alzheimer’s disease using G72 ProteinSLC7A11 mRNA as biomarkers
Project Operator Chang Gung Medical Foundation
Project Host 林潔欣
The present technology provides a method for diagnosing Alzheimer's disease, including the following steps: detecting a blood sample taken from a human subject suspected of having Alzheimer's disease,the biomarker level is selected from G72 protein level, SLC7A11 mRNA expression level,a combination of the two,compared with a preset standard, wherein if the detected biomarker level in the blood sample is higher than the preset standard, the individual humans are thought to have Alzheimer's disease. Its area under the curve (AUC) can reach an excellent 0.915. This method is not affected by age,more suitable for un-medicated AD patients, revealing that it is a good tool for assisting the diagnosis of AD in clinical use.
Scientific Breakthrough
Current research on biomarkers of Alzheimer’s disease has focused on known pathological substrates, such as amyloid plaquesneurofibrillary tangles, but has not yet produced a usefuldefinitive diagnostic method. Furthermore, the drugs developed according to these pathological substrates have not yet been able to effectively improve the disease. The current technology is based on new mechanisms of DAAO activator (DAOA,named G72)(which modulates NMDA neurotransmission)cystine/glutamate antiporter system xc- (which modulates oxidative stress). The combination of G72SLC7A11 (xCT) ΔCT determined a favorable AUC between patients with Alzheimer’s diseasehealthy controls. There has been no similar product on the market.
Industrial Applicability
The number of patients suffering from AD is increasing rapidly around the world. However, there is still a lack of simpleaccurate diagnostic tools, therefore hampering its early diagnosistreatmentconsequently increasing family burdensocial cost. The current technology, which uses peripheral blood to preciselyeasily diagnose AD, can be further developed to diagnostic kits. Due to its fast, easy,low-invasive advantage, it can not only generate huge industrial value but thereafter also reduce the social cost. The technique, which has obtained domesticinternational patents based upon entirely new mechanism, has great potential to develop domesticforeign markets.
Keyword Alzheimer’s disease G72 protein SLC7A11 mRNA Biomarker D-amino acid oxidase (DAAO) activator (DAOA) Dementia Peripheral blood NMDA Cognitive aging Diagnostic tool
  • Contact
  • Chieh-Hsin Lin
other people also saw